Steven D. Gore, MD

New Recruit in Medicine (Hematology); Director of Hematologic Malignancies

Physician Biography

Dr. Gore came to Yale in November 2013 following 23 years on the faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. Dr. Gore is an international authority on myelodysplastic syndromes (MDS) and other forms of leukemia. He is particularly known for his novel clinical and translational trials in MDS and leukemia, using drugs which target epigenetic abnormalities in leukemia cells. He is a leader in the leukemia effort of the Eastern Cooperative Oncology Group and is a member of the MDS committee of the National Cancer Care Network.

Clinical Interests

  • Hematology
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Hematology Program

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation

Edit this profile

Contact Info

Steven D. Gore, MD
Patient Care Location
Yale Cancer Center-YNHHYale-New Haven Hospital
20 York Street, Ste 7th Floor

New Haven, CT 06510
Office Location
Yale Cancer Center300 George Street, Ste 7th Floor
New Haven, CT 06511
Mailing Address
Yale Cancer Center25 York Street
PO Box 208028

New Haven, CT 06520-8028

Curriculum Vitae